Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Sees Large Decrease in Short Interest

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the recipient of a large decline in short interest in May. As of May 29th, there was short interest totaling 39,018 shares, a decline of 73.7% from the May 14th total of 148,551 shares. Based on an average trading volume of 4,357,454 shares, the short-interest ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Lakewood-Amedex Biotherapeutics Stock Down 4.7%

NASDAQ:LABT traded down $0.04 during mid-day trading on Thursday, hitting $0.72. 164,681 shares of the company’s stock traded hands, compared to its average volume of 3,041,669. Lakewood-Amedex Biotherapeutics has a twelve month low of $0.59 and a twelve month high of $9.82.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.